Latest Options News

Arcadia Minerals reports ongoing joint venture discussions across its Namibian projects and initiates a competitive bidding process for Swanson Tantalum Mine construction financing following a funding agreement termination.

First Au Limited updates on its Victorian and Western Australian gold exploration projects, announces key board changes, and completes a $325,000 capital raise to support ongoing operations.

AustChina Holdings Limited reports steady progress in its Blackall Coal Project and copper investments, while exploring innovative coal processing technologies and assessing new mineral resource opportunities.

Rapid Lithium Ltd has completed its acquisition of Midwest Lithium and initiated a $2 million entitlement offer, marking a strategic pivot towards US and Canadian exploration projects.

Mithril Silver and Gold Limited reports strong drilling results at its Copalquin gold-silver project in Mexico, backed by a $12.5 million placement to fund an expanded 35,000-metre 2025 exploration program.

Terra Metals reports robust drilling results from its Dante Project, revealing high-grade titanium alongside copper, PGMs, and vanadium, while securing an option to expand its tenement holdings.

Papyrus Australia Ltd reported a $284,000 net cash outflow for the December 2024 quarter, reflecting abnormal expenses but maintaining a solid funding runway through existing facilities and strategic initiatives.

Cauldron Energy’s December quarter report highlights a breakthrough uranium discovery at Manyingee South within the Yanrey Project, alongside a successful $4 million capital raise to fund ongoing exploration.

Audio Pixels Holdings Limited reports significant technical progress in its Digital Sound Reconstruction technology and secures additional funding through convertible notes, while continuing to navigate ASX suspension challenges.

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.

Vectus Biosystems reports completion of Phase Ib trials for its lead drug VB0004 and a robust cash position bolstered by a significant R&D tax refund, setting the stage for licensing discussions.

Dotz Nano Limited has landed its first commercial order for DotzShield in the U.S. and made significant strides in carbon capture technology development, including a new sorbent for Direct Air Capture and a strategic collaboration with Bar-Ilan University.